Fig. 2

CXCR7 contributes to osteogenic and chondrogenic differentiation of MSCs. a Verification of CXCR7 overexpression in MSCs lentivirally transduced with control vector (CVT) or CXCR7-expressing vector (CXCR7) for 72 h. Data are means ± SD (n=9). *P < 0.0001 compared with wild-type MSCs (WT). b Changes in osteogenic and chondrogenic genes in MSCs with or without CXCR7 overexpression incubated with osteogenic or chondrogenic induction medium for 72 h. Data are means ± SD (n=9). *P < 0.0001 compared with wild-type MSCs (WT). c The protein levels of osteopontin and aggrecan in MSCs with or without CXCR7 overexpression incubated with osteogenic or chondrogenic induction medium for 72 h. Data are means ± SD (n=9). *P < 0.001 compared with wild-type MSCs (WT). d Alizarin red and Alcian blue staining and their quantitation in MSCs with or without CXCR7 overexpression incubated with osteogenic or chondrogenic induction medium for 21 days. Data are means ± SD (n=9). *P < 0.001 compared with wild-type MSCs (WT). The protein levels of osteopontin or aggrecan (e) and quantitation of Alizarin red and Alcian blue staining (f) in MSCs with or without the CXCR7 antagonist, CCX771, or agonist, TC14012, incubated with osteogenic or chondrogenic induction medium for 72 h and 21 days, respectively. Data are means ± SD (n=9). *P < 0.001 compared with the untreated group (WT)